ACC Scientific Session - American College of Cardiology Scientific Session

Investigators found that 89% of individuals with cardiovascular disease consumed more than 1500 mg of sodium daily.

Bristol Myers Squibb will also present findings on apixaban (Eliquis) at the American College of Cardiology Annual Scientific Session and Expo.

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.

The finding did not reach statistical significance in the primary composite endpoint.

The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

The Librexia program includes 3 concurrent clinical trials, investigating milvexian’s use for ischemic stroke, acute coronary syndrome, and atrial fibrillation

Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.

The proportion of patients prescribed high-intensity statin therapy increased by 3.8% across all clinics in the intervention arm.

Study participants without co-pays were slightly more likely to take their medications as prescribed for several medication classes.

Sheldon Litwin, MD, a cardiologist at the Medical University of South Carolina, discussed the significant recent advances in anti-obesity drugs.

Donna Ryan, MD, discussed her presentation about pharmacological approaches for obesity, which patients they are indicated for, and considerations for pharmacists.

The 2022 American Heart Association, American College of Cardiology, and Heart Failure Society of America guidelines recommend SGLT2 inhibitors for nearly all patients in cardiovascular practice.

Although scientists have long been working on anti-obesity medications, several key failures in recent decades have made this a challenge.

Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.

Findings from the AFFIRM trial found increased risks after stopping oral anticoagulant therapy after rhythm control, and the same is true for stopping treatment with oral anticoagulants after successful ablation.

In an interview with Pharmacy Times, Anastasia Armbruster, PharmD, FACC, BCCP, discussed her presentation at the American College of Cardiology 2023 Scientific Session.

Although pharmacokinetics and dynamics can be complex, particularly in patients with cancer, pharmacists play a key role in the various considerations and treatment decisions.

Pharmacists are essential health care team members who can be empowered to help initiate fixed-dose combinations, according to an expert panel at the American College of Cardiology 2023 Scientific Session.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

Health care providers can manage “fake news” about statins, including their indications and misinformation regarding liver and kidney damage.

Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein-cholesterol.

In addition to the hundreds of sessions and events, ACC has partnered with the World Heart Federation, bringing an international focus to the meeting.

Patients with atherosclerotic cardiovascular disease who were already receiving statin therapy had a reduction in adverse cardiovascular outcomes with earlier initiation of evolocumab.

American College of Cardiology President Edward Fry, MD, FACC, discussed what attendees can look forward to at the 2023 Scientific Sessions.

Dave Dixon, PharmD, discussed heart failure treatments in the pipeline and what he sees for the future of pharmacists in cardiovascular care.

With therapeutics developing quickly in the cardiovascular space, pharmacists are more important than ever.

Pharmacy Times spoke with Dave Dixon, PharmD, to learn more about his presentation titled “New Pharmacologic Therapies for Heart Failure.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Session at American College of Cardiology Scientific Sessions 2022 highlight treatments for symptomatic obstructive hypertrophic cardiomyopathy.